Cerebral Edema in Patients with severe Hemispheric Syndrome: Incidence, Risk Factors, and Outcomes—Data from SITS-ISTR

Article information

J Stroke. 2023;25(1):101-110

Publication date (electronic) : 2022 December 6

doi : https://doi.org/10.5853/jos.2022.01956

Irene Escudero-Martínez^,a,b, Magnus Thorén^c,d, Peter Ringleb^e, Ana Paiva Nunes^f, Manuel Cappellari^g, Viiu-Marika Rand^h, Piotr Sobolewskiⁱ, Jose Egido^j, Danilo Toni^k, Shih-Yin Chen^l, Nicole Tsao^l,*, Niaz Ahmed^d,m

^aDepartment of Neurology, University Hospital La FE, Valencia, Spain

^bNeurovascular Research Laboratory, Biomedicine Institute IBiS, Sevilla, Spain

^cDepartment of Neurology, Danderyd Hospital, Stockholm, Sweden

^dDepartment of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

^eDepartment of Neurology, Heidelberg University Hospital, Heidelberg, Germany

^fDepartment of Neurology, Sao Jose Hospital, University Hospital Lisboa, Lisboa, Portugal

^gDepartment of Neuroscience, Integrate University Hospital, Verona, Italy

^hDepartment of Neurology, North Estonia Medical Centre Foundation, Tallinn, Estonia

ⁱDepartment of Neurology and Stroke Unit in Sandomierz, Collegium Medicum, Jan Kochanowski University in Kielce, Kielce, Poland

^jStroke Unit, Department of Neurology, San Carlos Clinic Hospital, Madrid, Spain

^kDepartment of Human Neurosciences, Sapienza University of Rome, Rome, Italy

^lBiogen, Cambridge, MA, USA

^mDepartment of Neurology, Karolinska University Hospital, Stockholm, Sweden

Correspondence: IreneEscudero-Martínez Stroke Unit, Department of Neurology, University Hospital La Fe, Av. Fernando Abril 106, 46026, Valencia, Spain Tel: +34-96-124-4000 Fax: +34-96-124-6241 E-mail: escudero_ire@gva.es

*Current affiliation: Sanofi Genzyme, Cambridge, MA, USA

Received 2022 June 14; Revised 2022 August 2; Accepted 2022 August 11.

Abstract

Introduction

Cerebral edema (CED) in acute ischemic stroke worsens the prognosis and can, if severe, cause life-threatening intracranial tissue shifts [1]. In patients presenting with cerebral ischemia, the size of the ensuing infarct is dependent on several factors, including treatment aimed at reperfusion of the occluded artery. Infarct size is a major determinant of the extent and clinical severity of the ensuing edema and potential hemorrhage. Severe hemispheric syndrome (SHS) is defined as having a high National Institutes of Health Stroke Score (NIHSS) score at baseline, as a marker of a large area of cerebral ischemia [2]. In cerebral ischemia caused by supratentorial large vessel occlusion (LVO), the risk of life-threatening edema is highest in occlusion of terminal internal carotid artery or the main trunk of the middle cerebral artery (MCA). This condition is called large hemispheric infarction (LHI). The most common guideline-supported definition of LHI refers to “a large ischemic stroke affecting the total or subtotal territory of the MCA, involving the basal ganglia at least partially, with or without involvement of the adjacent territories.” [3,4] Among patients with supratentorial ischemia, approximately 1 in 10 develops a subtotal or complete MCA infarction [2]. The clinical deterioration caused by edema after a large MCA infarction is usually observed within 48 hours after symptom onset with one third of the patients undergoing early deterioration within 24 hours [5]. The rate of mortality is close to 80% within a few days, unless treated with early surgery [6].

Data from previous studies indicate that the risk for life-threatening CED is strongly associated with increasing infarct size, or other variables correlated to infarct size such as need for mechanical ventilation, large perfusion deficit and involvement of more than one vascular territory [7-9]. A previous Safe Implementation of Treatments in Stroke (SITS)-International Stroke Treatment Registry (ISTR) paper reported that the most important baseline predictors for CED were higher NIHSS score, hyperdense artery sign (HAS), higher blood glucose, decreased level of consciousness (LOC) and signs of infarct at baseline imaging scan [10].

Methods

Results

Patients (n=8,560) that presented with SHS developed pSHS at 24 hours. Figure 1 shows a flowchart of the study. Table 1 shows baseline characteristics and univariate analysis of patients with SHS and pSHS, stratified by grade of CED. Median age was 77 and median NIHSS was 21 (interquartile range, 18 to 23); 46.3% were men. Of the total SHS and LHI patients, 7,035 patients (82.2%) received IVT, 903 (10.5%) IVT and EVT, and 622 (7.3%) EVT alone. Of 7,949 patients with available CED data, 3,780 (47.6%) had any CED and 2,297 (28.9%) were moderate/severe. Supplementary Table 1 shows baseline characteristics and Supplementary Table 2 shows the clinical and radiological outcomes of any SHS, any pSHS, both SHS & pSHS, and no SHS nor pSHS populations. Patients with pSHS had worse outcomes than SHS. pSHS patients had a higher rate of SICH and any type of hemorrhages and death and a lower rate of functional independence than SHS patients.

Figure 1.

Study flow chart. SITS, Safe Implementation of Treatments in Stroke; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Score; SHS, severe hemispheric syndrome; pSHS, persistent severe hemispheric syndrome.

Table 1.

Baseline characteristics and univariate analysis by grade of cerebral edema

Univariate analysis

As seen in Tables 1 and 2, patients with moderate or severe CED were significantly younger and had more frequently signs of acute infarction and HAS at baseline imaging scans. Moreover, patients with moderate/severe edema presented higher values of blood glucose at admission and oral antidiabetic treatment. The proportion of patients with previous stroke was lower in the moderate/severe CED group and the percentage of patients with pre-stroke mRS 0 was higher. Decreased LOC as measured by item 1a in the NIHSS score was more frequent in the moderate/severe CED group. In 175 patients (2%) decompressive hemicraniectomy was performed. This percentage ranged from 0.6% in no CED, 0.9% in mild CED, 2.2% in moderate, and 8.2% in severe CED (P<0.001).

Table 2.

Univariate analysis in patients with SHS and pSHS by grade cerebral edema

Multivariable analysis

Table 3 shows results from a multivariable model for prediction of moderate to severe CED with RR and 95% confidence intervals. Age <50 years (RR, 1.56), signs of acute infarction on baseline imaging (RR, 1.29), HAS (RR, 1.39), blood glucose >128.5 mg/dL (RR, 1.21), and decreased LOC (RR, 1.14) were associated with moderate/severe CED (for all P<0.05).

Table 3.

Multivariable model for prediction of moderate and severe CED with RR (Poisson regression, with GEE)

Long-term outcomes

Table 4 shows multivariable logistic regression models for the effect of CED on long term outcomes. The adjusted odds ratio (aOR) showed that patients with any CED versus no CED (aOR, 0.36), severe CED versus no, mild, or moderate CED combined (aOR, 0.42), and moderate and severe CED versus no or mild CED (aOR, 0.35) were less likely to achieve functional independence defined by mRS 0–2 at 90 days. Regarding mortality, the presence of CED in any degree, moderate and severe and severe were associated with a higher risk for death at 90 days, and the risk increased with the severity of CED (aOR, 1.58 for any; aOR, 2.54 for moderate and severe; and aOR, 3.94 for severe).

Table 4.

Effect of CED on long-term prognostic outcomes among patients with SHS & pSHS and available CED information

Discussion

In this large observational study based on multinational data of acute ischemic stroke patients treated with recanalization therapy, we found that almost half of the patients with severe ischemic stroke according to SHS and pSHS definitions had any degree of CED and almost a third of them had moderate to severe CED. A previous Chinese study found the same rate of severe CED in LHI patients [14]. However, when all types of ischemic strokes irrespective of severity are analyzed, any type of CED, detected by the SITS-MOST Edema Scale [12] at 22 to 36 hours imaging was around one in four patients. The incidence of moderate and severe CED was similar, about 5% [10]. For the purpose of our study, we selected patients with severe stroke symptoms at baseline (SHS) and a clinical proxy using NIHSS score at 24 hours (pSHS) for severe strokes after repersfusion treatment. Our study population with SHS and pSHS are expected to have higher prevalence of CED than the general ischemic stroke population.

In this SHS & pSHS population with high risk of CED, the most important predictors for moderate/severe CED development were young age, high blood glucose levels, signs of acute infarction or HAS on baseline neuroimaging and decreased LOC at admission. Predictors for CED in our study on severe stroke patients are consistent with previous single center and multicenter studies that included broader populations. The strongest predictors for moderate/severe CED development were a younger age and HAS on baseline neuroimaging. These findings have been previously reported [10,12,15].

Elderly patients who developed large infarctions may have brain atrophy, and this may compensate for CED. HAS on baseline CT is an indirect finding of LVO and it is associated with SHS and LHI.

As previously reported, we also found that a higher blood glucose level at admission was a risk factor for CED development [10]. This consistent association between glucose levels and CED after a large ischemic stroke has been the basis of pre-and clinical research of glibenclamide as a potential treatment for these patients [16].

The association of recanalization therapies and CED remains unclear. In the line of our findings regarding signs of acute infarction at baseline, a recent meta-analysis has shown that in patients with LHI, EVT, and reperfusion were associated with severe CED only in the group with very large core volume [17].

Regarding long-term outcomes, the presence of any CED, moderate and severe and severe CED were independently associated with worse functional outcome, with a 60% decrease in the odds of functional independence. Our results regarding the effect of CED in functional outcome and mortality are consistent with a previous study in patients treated with IVT [9].

Presence of CED was associated with a higher risk of death at 90 days, including in-hospital mortality, and the risk increased from 1.5 to 4 times higher as compared to patients with no CED. Regarding treatment, randomized trials showed that surgical decompression reduced the risk of death, and meta-analyses of these trials showed that surgery also increased the chance of a favorable outcome [6,18].

Although being a well-known complication of large stroke, the management of CED remains a topic of discussion. The European Stroke Organization has recently published guidelines on the management of space-occupying brain infarction [19]. In this document, surgical decompression is recommended to reduce the risk of death and to increase the chance of a favorable outcome in adult patients aged up to and including 60years with space-occupying hemispheric infarction who can be treated within 48hours of stroke onset, and low-quality evidence to support this treatment in older patients. There is continued uncertainty about the benefit and risks of surgical decompression in patients with space-occupying hemispheric infarction if performed after the first 48hours. However, in a real-world setting, patients who undergo hemicraniectomy present frequently with complications that were underestimated in randomized clinical trials and may worsen the functional outcome, with 80% of survivors completely dependent (mRS 4–5) [20].

Recently, new guidelines on CED management in neurocritical care patients have been published [21]. For acute treatment, they suggest using either hypertonic sodium solutions or mannitol for the initial management of CED in patients with acute ischemic stroke (conditional recommendation, low-quality evidence), although neurological outcomes appear to be not affected. Previous guidelines state that there are insufficient data on the effect of hypothermia, barbiturates, or corticosteroids in the setting of ischemic cerebral swelling [3]. For these reasons, the management of patients with CED is still a challenge for stroke physicians, more clinical research is needed in early detection, prevention, and treatment of CED development.

This study presents some limitations. First, it is an observational study based on retrospective analyses, although data were collected prospectively. Our findings were limited to those who received IVT or EVT treatments and might not be generalizable to those who did not receive either therapy. Moreover, there is a proportion of missing and unknown data in some variables, including some missed cases of fatal CED, that may have influenced the results. Thus, there is a potential bias of patient selection. The associations observed in this study should be viewed as hypotheses-generating and need confirmation in further studies. Finally, another limitation is that we have defined persistent severe neurological deficit according to clinical criteria and not according to radiological findings, as data regarding final infarct volume were not available due to the lack of a centralized reading of the CTs. This could introduce some interobserver variability. However, pooled treatment of moderate/severe versus no/mild edema would tend to reduce this effect. The strengths of this study are the very large international sample size and consistent results with previous single and multicenter studies.

Conclusions

In conclusion, in patients with clinical signs of extensive ischemia, the most important predictors of moderate/severe CED development were young age, high blood glucose, signs of acute infarct, HAS on baseline scans and decreased LOC. The presence of any, moderate/severe, and severe CED were associated with worse functional outcome and a higher risk of death at 3 months, that increases proportionally with the severity of CED.

Supplementary materials

Article information Continued